| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/15/2006 | WO2006061493A1 Substituted indoles, compositions containing them, method for the production thereof and their use |
| 06/15/2006 | WO2006061428A2 Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain |
| 06/15/2006 | WO2006061427A1 5-amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropxy)benzyl]-8-methylnonanamides |
| 06/15/2006 | WO2006061426A1 ω-PHENYLOCTANAMIDES |
| 06/15/2006 | WO2006061418A2 Methods and agents useful in treating conditions characterized by mucus hyperproduction/hypersecretion |
| 06/15/2006 | WO2006061417A2 Macrocyclic quinazole derivatives and their use as mtki |
| 06/15/2006 | WO2006061415A1 2,4 (4,6) pyrimidine derivatives |
| 06/15/2006 | WO2006061392A2 Substituted tetracyclic tetrahydrofuran, pyrrolidine and tetrahydrothiophene derivatives |
| 06/15/2006 | WO2006061379A1 Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition |
| 06/15/2006 | WO2006061378A1 Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition |
| 06/15/2006 | WO2006061377A1 Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition |
| 06/15/2006 | WO2006061376A1 Aryloxyethylamine derivatives with a combination of partial d0pamine-d2 receptor agonism and serotonin reuptake inhibition |
| 06/15/2006 | WO2006061374A1 Benzdioxane piperazine derivatives with a combination of affinity for dopamine-d2 receptors and serotonin reuptake sites |
| 06/15/2006 | WO2006061366A1 Pyrrolidin-2-one derivatives for use as dp1 receptor agonists |
| 06/15/2006 | WO2006061364A1 Process for the preparation of carvedilol and its enantiomers |
| 06/15/2006 | WO2006061351A1 Oral suspension comprising meloxicam |
| 06/15/2006 | WO2006061341A1 Use of propionyl l-carnitine for the preparation of a high-dose medicament for the treatment of peripheral arterial disease |
| 06/15/2006 | WO2006061340A2 Stable, hormone-containing (intermediate) product |
| 06/15/2006 | WO2006061336A2 Oral compositions for absorption of phosphorus compounds |
| 06/15/2006 | WO2006061309A1 Process for the preparation of drospirenone |
| 06/15/2006 | WO2006061253A2 Combination of tyrosine kinase inhibitor and her-2/neu for cancer therapy |
| 06/15/2006 | WO2006061233A1 The use of medicament 4-(s)-(4-acetyl-piperazin-1-yl)-2-(r)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid, [1-(r)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide |
| 06/15/2006 | WO2006061214A1 Anthelmintic composition |
| 06/15/2006 | WO2006061212A1 3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors |
| 06/15/2006 | WO2006061199A1 Use of staurosporine derivatives for the treatment of multiple myeloma |
| 06/15/2006 | WO2006061156A2 Medicament for hygienic application inside the ear |
| 06/15/2006 | WO2006061155A2 Stabilisation of glucocorticoid esters with acids |
| 06/15/2006 | WO2006061147A1 1-phenyl-3-piperazine-pyrazoles and pesticidal compositions of matter thereof |
| 06/15/2006 | WO2006061140A2 Composition of ssao substrates and metal compounds of the vla and vlb groups of the periodic table |
| 06/15/2006 | WO2006061136A2 Malonamide derivatives as inhibitors of gamma-secretase for the treatment of alzheimer’s disease |
| 06/15/2006 | WO2006061135A1 Phenyl-piperazin methanone derivatives |
| 06/15/2006 | WO2006061116A1 Pyrazine dicarboxamides and the use thereof |
| 06/15/2006 | WO2006061069A1 Multiparticulate form of administration, comprising nucleic acid-containing mucoadhesive active ingredients, and method for producing said form of administration |
| 06/15/2006 | WO2006060919A1 Novel spirotropane compounds and methods for the modulation of chemokine receptor activity |
| 06/15/2006 | WO2006060918A1 Novel spirotropane compounds and methods for the modulation of chemokine receptor activity |
| 06/15/2006 | WO2006060903A1 Signal peptides, nucleic acid molecules and methods of treatment |
| 06/15/2006 | WO2006060898A1 Method for treating inflammatory disorders |
| 06/15/2006 | WO2006060885A1 7-(2-cyclohexylidene-ethylidene)-spiro[5.5]undecanes useful for making pharmaceutical compositions |
| 06/15/2006 | WO2006060884A1 7-(2-cyclohexylidene-ethylidene)-spiro[4.5]decanes |
| 06/15/2006 | WO2006060878A1 Methods and compositions for adoptive immunotherapy |
| 06/15/2006 | WO2006060853A1 Treatment for cancer |
| 06/15/2006 | WO2006048911A3 Pharmaceutical or nutraceutical compositions containing chromium or iron complexes of alpha-lipoic acid |
| 06/15/2006 | WO2006047772A3 Tricyclic spacer systems for nonlinear optical devices |
| 06/15/2006 | WO2006044968A3 Combination therapy for treating viral infections |
| 06/15/2006 | WO2006044823A3 Heteroaryl-substituted alkyne compounds and method of use |
| 06/15/2006 | WO2006044790A3 Compositions and methods for prolonging survival of platelets |
| 06/15/2006 | WO2006044573A3 Reversible inhibitors of s-adenosyl-l-homocysteine hydrolase and uses thereof |
| 06/15/2006 | WO2006044425A3 Ophthalmic compositions for treating ocular hypertension |
| 06/15/2006 | WO2006044379A3 Novel curcumin analogues and uses thereof |
| 06/15/2006 | WO2006042479A9 Pharmaceutical composition and non dependence coffee comprising edible carboxylic acid and/or its acid salt and coffeine |
| 06/15/2006 | WO2006042324A3 Antifungal composition applicable to body tissue, preferably nails |
| 06/15/2006 | WO2006042103A3 Reversible inhibitors of cathepsin b |
| 06/15/2006 | WO2006041636A3 Amino substituted aryloxybenzylpiperidine derivatives |
| 06/15/2006 | WO2006037449A3 Iron complex for use in the treatment and/or prevention of nutritional disorders |
| 06/15/2006 | WO2006036816A3 Chemical compounds |
| 06/15/2006 | WO2006034822A8 Novel substituted thiophencarboxylic acid amides, production thereof and use thereof as medicaments |
| 06/15/2006 | WO2006034392A9 Therapeutic quinones |
| 06/15/2006 | WO2006026196A3 Androgen receptor modulators |
| 06/15/2006 | WO2006026135A3 Substituted biaryl piperazinyl-pyridine analogues |
| 06/15/2006 | WO2006024044A8 Composition and method for altering levels of or sensitivity to adenosine with analogs of dehydroepiandrostone |
| 06/15/2006 | WO2006023778A3 Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof |
| 06/15/2006 | WO2006023194A3 Improved photosensitizer formulations and their use |
| 06/15/2006 | WO2006021000A3 Substituted thienopyrrole carboxylic acid amides, pyrrolothiazole carboxylic acid amides, and related analogs as inhibitors of casein kinase i epsilon |
| 06/15/2006 | WO2006020534A3 Stabilized desloratadine composition |
| 06/15/2006 | WO2006019685A3 Compounds and their preparation for the treatment of alzheimer's disease by inhibiting beta-amyloid peptide production |
| 06/15/2006 | WO2006018222A8 Hydrates and polymorphs of 4-[[(7r)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-4-6-oxo-2-piperidinyl]amino]-3-methoxy-n-(1-methyl-4-piperidinyl) benzamide, methods for the production thereof, and use thereof as medicaments |
| 06/15/2006 | WO2006018221A8 Dihydropteridinone infusion solution having a long shelf life |
| 06/15/2006 | WO2006017761A3 Epothilone analogues as therapeutic agents |
| 06/15/2006 | WO2006015860A3 Pyrazole derivatives for treating conditions mediated by activation of the adenosine a2b or a3 receptor |
| 06/15/2006 | WO2006015389A3 Methods and compositions for enhancing the efficacy and specificity of rna silencing |
| 06/15/2006 | WO2006013369A3 Compositions forming non-lamellar dispersions |
| 06/15/2006 | WO2006013209A3 Compounds for inhibiting copper-containing amine oxidases and uses thereof |
| 06/15/2006 | WO2006010838A3 Products containing at least one anticancer active principle with low diffusion and an immunostimulatory active principle |
| 06/15/2006 | WO2006010775A8 Tyrosine derivatives as ppar-gamma-modulators |
| 06/15/2006 | WO2006007323A3 Dosage forms for low solubility and/or low dissolution rate free acid pharmaceutical agents |
| 06/15/2006 | WO2006002434A3 Novel indazole carboxamides and their use |
| 06/15/2006 | WO2005123076A3 Pharmaceutical compositions |
| 06/15/2006 | WO2005113526A3 Metabolites of 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]-thiomorpholin-3-one |
| 06/15/2006 | WO2005112958A3 Rapid setting calcium phosphate cements |
| 06/15/2006 | WO2005110436A3 Macromolecule-containing sustained release intraocular implants and related methods |
| 06/15/2006 | WO2005110399A3 Zinc-binding groups for metalloprotein inhibitors |
| 06/15/2006 | WO2005105094A3 Cancer treatment method |
| 06/15/2006 | WO2005102269A3 An amine drug-containing slow-release granule preparation based on particles with a coating layer and the corresponding method of production |
| 06/15/2006 | WO2005097112A3 Ion channel modulators |
| 06/15/2006 | WO2005087192A3 Salmeterol inhalation formulations |
| 06/15/2006 | WO2005079759A3 Pharmaceutical composition for oral application and method for preparing thereof |
| 06/15/2006 | WO2005074882A3 Flat system for using in the oral cavity |
| 06/15/2006 | WO2005072272A3 Compositions and methods for generating short double-stranded rna using mutated rnase iii |
| 06/15/2006 | WO2005065718A3 Antitumour treatments with metxia-p450 and cyclophosphamide or 5t4 vaccine |
| 06/15/2006 | WO2005063211A3 Method of producing lipid complexed camptothecin-carboxylate |
| 06/15/2006 | WO2005060517A3 Genes commonly regulated by different classes of antidepressants |
| 06/15/2006 | WO2005013915A3 Novel indications for transforming growth factor-beta regulators |
| 06/15/2006 | WO2005007134A8 Powdery formulations for inhalation, containing a novel anticholinergic agent |
| 06/15/2006 | WO2004098519A3 Ginkgo biloba extract as a treatment for therapeutic induced neurotoxicity |
| 06/15/2006 | WO2004091492A3 Computer-based model for identification and characterization of non-competitive inhibitors of nicotinic acetylcholine receptors and related ligand-gated ion channel receptors |
| 06/15/2006 | WO2004037978A3 Methods of reducing the activity of and reducing the concentration of a mutant kit protein |
| 06/15/2006 | WO2001082928A9 Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism |
| 06/15/2006 | US20060130186 Novel high yielding multiple disease resistant/tolerant stable variety 'Madakini' of opium poppy |
| 06/15/2006 | US20060130169 Transgenic non-human mammals that reproduce human pathologies of stem cell origins, such as chromosomal anomalies associated with chronic myeloid leukemia, B-cell acute lymphoblastic leukemia, T-cell acute or lymphoblastic leukemia, or with the migration of hematopoietic or embryonic stem calls. |
| 06/15/2006 | US20060130168 Using transgenic non-human mammals that reproduce human pathologies of stem cell origins, such as chromosomal anomalies associated with chronic myeloid leukemia, B-cell acute lymphoblastic leukemia, T-cell acute or lymphoblastic leukemia, or with the migration of hematopoietic or embryonic stem cells |